please find enclosed herewith Audited Financial results for the quarter and financial year ended 31st March, 2026.
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Wockhardt reported a strong turnaround in FY2026 with standalone revenue growing 24% to Rs 1,739 Crore from Rs 1,402 Crore. Profit after tax swung dramatically from a loss of Rs 12 Crore to a profit of Rs 317 Crore. The auditors gave an unmodified (clean) opinion. Exceptional items included a Rs 35 Crore gain from Dr. Reddy's settlement, partially offset by Rs 10 Crore for new labour code impact and Rs 110 Crore charge for deconsolidation of US subsidiaries (which filed for Chapter 7 bankruptcy). Consolidated revenue grew 12% to Rs 3,373 Crore with PAT of Rs 199 Crore versus a loss of Rs 57 Crore in FY2025. The board also sought shareholder approval to raise funds via equity or securities.
Positive for shareholders - the company returned to profitability with strong revenue growth and positive operating cash flow of Rs 241 Crore, reversing the previous year's negative cash flow. The US exit is a strategic shift but involves one-time exceptional charges.